Cargando…

Eriochloa villosa Alleviates Progression of Benign Prostatic Hyperplasia in vitro and in vivo

INTRODUCTION: Benign prostatic hyperplasia (BPH) is a non-neoplastic proliferative disease of the prostate. Eriochloa villosa (EV) reportedly possesses various pharmacological activities, including anti-lipase activity and modulation of various antioxidative enzymes. In this study, we investigate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Baek, Eun Bok, Hwang, Youn-Hwan, Park, Suyoung, Hong, Eun-Ju, Won, Young-Suk, Kwun, Hyo-Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519014/
https://www.ncbi.nlm.nih.gov/pubmed/36187165
http://dx.doi.org/10.2147/RRU.S381713
_version_ 1784799311202091008
author Baek, Eun Bok
Hwang, Youn-Hwan
Park, Suyoung
Hong, Eun-Ju
Won, Young-Suk
Kwun, Hyo-Jung
author_facet Baek, Eun Bok
Hwang, Youn-Hwan
Park, Suyoung
Hong, Eun-Ju
Won, Young-Suk
Kwun, Hyo-Jung
author_sort Baek, Eun Bok
collection PubMed
description INTRODUCTION: Benign prostatic hyperplasia (BPH) is a non-neoplastic proliferative disease of the prostate. Eriochloa villosa (EV) reportedly possesses various pharmacological activities, including anti-lipase activity and modulation of various antioxidative enzymes. In this study, we investigate the therapeutic potential of EV against BPH in a testosterone-induced BPH rat model. METHODS: Rats were subjected to a daily subcutaneous injection of testosterone (3 mg kg(−1)) for 4 weeks to induce BPH. Along with testosterone, rats in the treatment group were administered finasteride (10 mg kg(−1)) or EV (150 mg kg(−1)) via oral gavage. Prostatic cancer (LNCaP) cell line was used to examine the effect of EV. RESULTS: Finasteride and EV significantly decrease the relative prostate weight, serum levels of dihydrotestosterone and testosterone, and prostate epithelial thickness. Testosterone injection induced prostatic hyperplasia and proliferating cell nuclear antigen expression; however, EV treatment significantly attenuated these effects. Moreover, finasteride- and EV-treated rats exhibit an increase in the number of TUNEL-positive cells and reduced Bcl-2 expression in the prostate tissues compared with the testosterone-treated animals. Furthermore, EV suppresses inflammatory cytokines, including interleukin (IL)-6 and IL-8, in the prostate tissues. Meanwhile, the expression of inflammatory mediator cyclooxygenase-2 is consistently upregulated in testosterone-treated rats, whereas EV treatment significantly reverses this effect. Notably, EV treatment suppresses malondialdehyde (MDA) levels and upregulates testosterone-induced catalase (CAT) expression. In addition, EV suppresses expression of androgen receptor (AR) and prostate-specific antigen (PSA) induced by testosterone in LNCaP cells. CONCLUSION: The present study results suggest that EV regulates prostatic proliferation, apoptosis, response to inflammation, and oxidative stress in the BPH rat model, and may, therefore, serve as a useful therapeutic agent for BPH.
format Online
Article
Text
id pubmed-9519014
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-95190142022-09-29 Eriochloa villosa Alleviates Progression of Benign Prostatic Hyperplasia in vitro and in vivo Baek, Eun Bok Hwang, Youn-Hwan Park, Suyoung Hong, Eun-Ju Won, Young-Suk Kwun, Hyo-Jung Res Rep Urol Original Research INTRODUCTION: Benign prostatic hyperplasia (BPH) is a non-neoplastic proliferative disease of the prostate. Eriochloa villosa (EV) reportedly possesses various pharmacological activities, including anti-lipase activity and modulation of various antioxidative enzymes. In this study, we investigate the therapeutic potential of EV against BPH in a testosterone-induced BPH rat model. METHODS: Rats were subjected to a daily subcutaneous injection of testosterone (3 mg kg(−1)) for 4 weeks to induce BPH. Along with testosterone, rats in the treatment group were administered finasteride (10 mg kg(−1)) or EV (150 mg kg(−1)) via oral gavage. Prostatic cancer (LNCaP) cell line was used to examine the effect of EV. RESULTS: Finasteride and EV significantly decrease the relative prostate weight, serum levels of dihydrotestosterone and testosterone, and prostate epithelial thickness. Testosterone injection induced prostatic hyperplasia and proliferating cell nuclear antigen expression; however, EV treatment significantly attenuated these effects. Moreover, finasteride- and EV-treated rats exhibit an increase in the number of TUNEL-positive cells and reduced Bcl-2 expression in the prostate tissues compared with the testosterone-treated animals. Furthermore, EV suppresses inflammatory cytokines, including interleukin (IL)-6 and IL-8, in the prostate tissues. Meanwhile, the expression of inflammatory mediator cyclooxygenase-2 is consistently upregulated in testosterone-treated rats, whereas EV treatment significantly reverses this effect. Notably, EV treatment suppresses malondialdehyde (MDA) levels and upregulates testosterone-induced catalase (CAT) expression. In addition, EV suppresses expression of androgen receptor (AR) and prostate-specific antigen (PSA) induced by testosterone in LNCaP cells. CONCLUSION: The present study results suggest that EV regulates prostatic proliferation, apoptosis, response to inflammation, and oxidative stress in the BPH rat model, and may, therefore, serve as a useful therapeutic agent for BPH. Dove 2022-09-24 /pmc/articles/PMC9519014/ /pubmed/36187165 http://dx.doi.org/10.2147/RRU.S381713 Text en © 2022 Baek et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Baek, Eun Bok
Hwang, Youn-Hwan
Park, Suyoung
Hong, Eun-Ju
Won, Young-Suk
Kwun, Hyo-Jung
Eriochloa villosa Alleviates Progression of Benign Prostatic Hyperplasia in vitro and in vivo
title Eriochloa villosa Alleviates Progression of Benign Prostatic Hyperplasia in vitro and in vivo
title_full Eriochloa villosa Alleviates Progression of Benign Prostatic Hyperplasia in vitro and in vivo
title_fullStr Eriochloa villosa Alleviates Progression of Benign Prostatic Hyperplasia in vitro and in vivo
title_full_unstemmed Eriochloa villosa Alleviates Progression of Benign Prostatic Hyperplasia in vitro and in vivo
title_short Eriochloa villosa Alleviates Progression of Benign Prostatic Hyperplasia in vitro and in vivo
title_sort eriochloa villosa alleviates progression of benign prostatic hyperplasia in vitro and in vivo
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519014/
https://www.ncbi.nlm.nih.gov/pubmed/36187165
http://dx.doi.org/10.2147/RRU.S381713
work_keys_str_mv AT baekeunbok eriochloavillosaalleviatesprogressionofbenignprostatichyperplasiainvitroandinvivo
AT hwangyounhwan eriochloavillosaalleviatesprogressionofbenignprostatichyperplasiainvitroandinvivo
AT parksuyoung eriochloavillosaalleviatesprogressionofbenignprostatichyperplasiainvitroandinvivo
AT hongeunju eriochloavillosaalleviatesprogressionofbenignprostatichyperplasiainvitroandinvivo
AT wonyoungsuk eriochloavillosaalleviatesprogressionofbenignprostatichyperplasiainvitroandinvivo
AT kwunhyojung eriochloavillosaalleviatesprogressionofbenignprostatichyperplasiainvitroandinvivo